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Verotoxins induce apoptosis in human renal tubular epithelium de-
rived cells. Apoptosis mediated by verotoxins (VTs) has been identified in
a renal carcinoma cell line, ACHN cells, which are an in vitro model of
renal tubular epithelial cells. ACHN cells express the renal tubular marker
CD24 as well as globotriaosyl ceramide/CD77, the receptor for VTs. VT
binding to the ACHN cell surface was confirmed by positive staining with
antibodies to the VTs. Treatment of ACHN cells with VTs induced
prompt growth inhibition and cell death, and fragmentation of the
genomic DNA in cells, typical of apoptosis, was observed. The expression
of apoptotic antigen 7A6 detected by APO2.7 antibody in ACHN cells
further supports the occurrence of apoptosis as a result of VT treatment.
Cycloheximide enhanced VT-mediated apoptosis of ACHN cells, suggest-
ing a strong correlation between the inhibition of protein synthesis and
VT-mediated apoptosis. Moreover, tumor necrosis factor-a had a syner-
gistic effect on VT-mediated apoptosis in ACHN cells. Considering the
above evidence together with the clinical evidence showing the presence of
apoptosis in the renal epithelium of a HUS patient, our results suggest a
VT-induced apoptotic mechanism in normal renal tubular epithelium that
may contribute to the pathogenesis of hemolytic uremic syndrome.
The hemolytic uremic syndrome (HUS) is characterized by the
triad of hemolytic anemia, acute renal failure, and thrombocyto-
penia [1]. The epidemic form of the HUS, which is preceded by a
diarrheal prodrome, has been shown to be strongly associated
with infection by verotoxin (VT) producing strains of Escherichia
coli (VTEC) [2]. Although the details of the pathogenesis of HUS
are still unclear, the damage of endothelial cells of glomerular
capillaries and renal arterioles mediated by VTs has been postu-
lated to play an important role [3, 4].
Several lines of evidence, however, imply that renal tubular
impairment also contributes to the development of HUS [5–10].
For an example, we previously demonstrated that VTs are cyto-
toxic for renal carcinoma line ACHN, an in vitro model of renal
tubular epithelial cells, which is 106- to 107-fold more sensitive to
them than human umbilical cord vascular endothelial cells
(HUVECs) [10].
In this study, we further characterized VT-mediated ACHN cell
damage and found that apoptotic cell death was part of the
process. The finding described in this paper could point out a new
mechanism of cell damage of renal tubular epithelium involved in
the pathogenesis of HUS caused by VTEC.
METHODS
Materials
VT-1 and VT-2 were prepared as described previously [11, 12].
The ACHN cell line was obtained from the American Type
Culture Collection (ATCC CRL 1611). The mouse monoclonal
antibodies used in this study were CD10 (IF-6 [13]), CD24 (L30
[14]), CD34 (QBEnd10; Coulter/Immunotec, Inc., Westbrook,
MA, USA), APO2.7 (Coulter), and CD77 (38.13; Coulter). An-
tiserum for VT-1 and VT-2 were prepared as described previously
[11, 12]. Fluorescein-conjugated secondary antibodies were pur-
chased from Jackson Laboratory, Inc. (West Grove, PA, USA).
The human recombinant cytokines including tumor necrosis fac-
tor (TNF)-a, interleukin-1 (IL-1)b, and interferon (INF)-g, were
purchased from Pepro Tech EC Ltd. (London, UK).
Immunofluorescence study
ACHN cell suspensions were produced by treating the cells with
PBS containing 0.1% NaN3 for five minutes, followed by pipet-
ting. The cells were then stained with monoclonal antibodies and
analyzed by flow cytometry (EPICS Profile and EPICS-XL;
Coulter) as described previously [13]. To detect VT binding, one
million of ACHN cells in suspension were incubated with and
without 0.1 mg/ml of VT-1 or VT-2 for one hour at 4°C. The cells
were then washed intensively with PBS and stained with either
control normal rabbit serum or polyclonal anti-VT-1 (VT-2)
antiserum. To detect 7A6 antigen, which is located in the cyto-
plasm, ACHN cells were harvested by trypsinization and fixed
followed by permeabilization prior to staining with PE-Cy5-
conjugated APO2.7 antibody, as described previously [15].
MTT assay
To assess growth and viability, ACHN cells were plated on
96-well plates (Corning, Inc., Corning, NY, USA) at a concentra-
tion of 1 3 104 cells in 100 ml of complete medium per well, with
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and without VT-1 (VT-2) or cytokines. MTT assays were per-
formed as described previously [16].
DNA fragmentation assay
ACHN cells were assayed for DNA ladder formation by gel
electrophoresis. After treatment with and without VTs, DNAs
were extracted from the cells, separated in 1% agarose gel by
electrophoresis and examined under UV light as described previ-
ously [17].
DNA fragmentation was also investigated in situ by the TUNEL
method using a TACSy 2 TdT(TBL) in situ apoptosis detection
kit (Trevigen, Inc., Gaithersburg, MD, USA). Experiments were
performed according to the manufacturer’s protocol.
To evaluate relative DNA contents, cells were stained with
propidium iodide (PI; Sigma-Aldrich Fine Chemicals, St. Louis,
MO, USA) then analyzed on by flow cytometry as described
previously [18].
RESULTS
Cell surface phenotype of ACHN cells
ACHN is a cell line derived from human renal tubular epithe-
lium adenocarcinoma. As reported in several papers including our
own, the epithelial components of renal tubules can be classified
according to the pattern of expression of hematopoietic cell
surface antigens [19–21]. Thus, we first examined ACHN cells by
using antibodies against CD leukocyte antigens. As shown in
Figure 1 A, ACHN cells were strongly positive for CD24 by flow
cytometry, but negative for CD10. ACHN cells were also found to
express low levels of Gb3/CD77, the functional receptor for VTs
[22–24]. Based on the distribution of various molecules in normal
renal tissue [21], ACHN cells in culture may correspond to the
epithelium of the distal tubule.
Verotoxin binding to ACHN cells
Since ACHN cells were found to express Gb3/CD77 on their
cell surface, we investigated whether the cells bind VTs. As shown
in the Figure 1B upper panels, rabbit anti-VT-1 antiserum labeled
ACHN cells pretreated with VT-1 as shown by flow cytometry. On
the other hand, ACHN cells not incubated with VT-1 failed to
react with anti-VT-1 antiserum, demonstrating the specificity of
the antiserum. In addition, anti-VT-2 antiserum did not show any
binding to VT-1-pretreated ACHN cells (data not shown). Similar
results were obtained by using a combination of VT-2 and
anti-VT-2 antiserum on ACHN cells (Fig. 1B, lower panels).
Cytotoxic effect of verotoxins on ACHN cells
Next we investigated whether VTs affect the growth and
survival of ACHN cells. When incubated with VT-1 or VT-2, the
viable number of ACHN cells assessed by MTT assay was
markedly decreased in a dose and time dependent manner (Fig.
2). The reduction of cell growth after treatment with VTs was due
to cell death as confirmed by trypan blue staining (data not
shown), showing a high sensitivity of ACHN cells to the cytotoxic
effect of VTs. VT-1 was significantly more cytotoxic to ACHN
cells than was VT-2 after three days of incubation (P , 0.01).
Each experiment was repeated more than three times indepen-
dently and similar results were obtained. Since VT-1 is more
cytotoxic to ACHN cells than VT-2, the following experiments
were mainly performed with VT-1.
Fig. 1. Analysis of antigen expression on the ACHN cell surface and
detection of verotoxin (VT) binding. (A) ACHN cells in suspension were
stained with specific monoclonal antibodies as indicated in the Figure and
analyzed by flow cytometry as described in Methods section. The histo-
gram obtained was superimposed on that of the negative control (indicat-
ed as CNT, the cells stained with isotype matched control immunoglobu-
lin) and displayed. X-axis, fluorescence intensity; Y-axis, relative cell
number. (B) To test VT binding, after incubation with (right panels) and
without (left panels) 0.1 mg/ml of VT-1 (upper panels) or VT-2 (lower
panels) for one hour at 4°C, ACHN cells in suspension were stained with
either rabbit anti-VT-1 anti-serum (upper panels) or anti-VT-2 anti-serum
(lower panels) and analyzed by flow cytometry. The histograms obtained
are displayed essentially as in A.
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Detection of apoptosis in the verotoxin-induced cell death of
ACHN cells
We conducted several experiments to investigate the possibility
that the cytotoxic effect of VTs involves an apoptotic pathway.
First, we examined the morphological appearance of ACHN cells
during VT-1 treatment. When ACHN cells were cultured in the
presence of VT-1, they showed condensed chromatin (Fig. 3A-b)
and cleaved nuclei (Fig. 3A-c), that is, findings typical of apopto-
sis. Moreover, typical apoptotic bodies were observed in cells that
floated after VT-1 treatment (Fig. 3A-d). However, no such
observations were made in untreated cells (Fig. 3A-a).
Next, we tested whether cleavage of nuclear DNA, a major
feature of apoptosis, occurs during the VT-induced death of
ACHN cells. As shown in Figure 3B, DNA prepared from ACHN
cells pretreated with VT-1 exhibited an oligonucleosomal ladder
fragmentation pattern on agarose gel electrophoresis. Cleavage of
the nuclear DNA in ACHN cells treated with VT-1 was also
confirmed by in situ detection by the TUNEL method, as shown in
Figure 3C. Some ACHN cells clearly incorporated biotinylated
nucleotides, indicating the occurrence of DNA fragmentation
induced by VT-1. Moreover, VT-1-induced cleavage of the nu-
clear DNA in ACHN cells was further confirmed by detecting
subploid cells with PI-staining (Fig. 4B).
Recently, a 38 kDa protein, 7A6, detected by APO2.7 antibody
was identified as an early stage marker of the apoptotic process in
various cells [18]. As shown in Figure 4A, APO2.7 clearly stained
ACHN cells treated with VT-1. No staining was observed when
APO2.7 was reacted with non-treated ACHN cells. These findings
clearly showed that apoptosis had indeed occurred in ACHN cells
following treatment with VT-1.
Since we observed a significant difference between VT-1 and
VT-2 in cytotoxic effects on ACHN cells, we compared the
abilities of VT-1 and VT-2 to induce apoptosis in these cells.
When the occurrence of apoptosis was evaluated by the either
appearance of 7A6 antigen (Fig. 4A) or the detection of subploid
cells (Fig. 4B), again, VT-1 showed significantly higher efficiency
of apoptosis induction in ACHN cells than did VT-2. This was
verified by statistical analysis (P , 0.001).
To better understand the mechanism of VT-mediated apoptosis
in ACHN cells, we conducted further experiments. First, we
examined the influence of cell concentration on VT-induced
apoptosis. ACHN cells were first seeded at different cell concen-
trations and then treated with VT-1. Subploid cell appearance was
markedly reduced as the cell concentration increased (Fig. 5),
showing the susceptibility of ACHN cells to VT-induced apoptosis
to be affected by initial cell concentration. We next examined the
effect of a protein synthesis inhibitor on VT-mediated apoptosis
in ACHN cells. Cycloheximide alone induced apoptosis in ACHN
cells at doses exceeding 25 mg/ml (data not shown). As shown in
Figure 6, a low dose (10 mg/ml) of cycloheximide did not induce
apoptosis but did increase the induction of subploid cells by VT-1
when added at the same time (P , 0.05). We also tested
Actinomycin D, a RNA synthesis inhibitor, and observed similar
results (data not shown). Each experiment was repeated more
than three times independently and similar results were obtained.
These findings strongly suggests that protein synthesis inhibition is
closely related to VT-mediated apoptosis in ACHN cells.
Effect of tumor necrosis factor-a on the verotoxin-mediated
cytotoxicity toward ACHN cells
As certain cytokines including TNF-a and IL-1b reportedly
enhance the cytotoxicity of VTs toward vascular endothelial cells
in vitro [3, 25–27], we tested whether or not these cytokines
synergistically affect the cytotoxicity of VTs to ACHN cells. No
significant reduction of cell viability was observed when ACHN
cells were treated with TNF-a alone (Fig. 7A, columns 1 and 2).
However, TNF-a was found to enhance the cell viability reduction
caused by VT-1 (Fig. 7A, columns 3 and 4, P , 0.05). Similar
results were obtained when IL-1b and INF-g were used (data not
shown).
In order to rule out the possibility of this observation being due
to direct growth inhibition of ACHN cells by TNF-a, we examined
the effect of TNF-a on VT-mediated apoptosis in ACHN cells by
detecting apoptotic antigen 7A6. As shown in Figure 7B, TNF-a
by itself did not induce the appearance of 7A6 antigens on ACHN,
but did markedly enhanced the 7A6 antigen expression induced
by VT-1 treatment. These results indicate that TNF-a has a
synergistic effect on VT-mediated apoptosis. Each experiment
Fig. 2. Cytotoxic effect of verotoxin (VT)-1 on
ACHN cells. ACHN cells (1 3 104 cells per 100
ml of medium per well) were incubated with
different concentrations of VT-1 or VT-2 as
indicated. After incubation for the periods
indicated, viable cell numbers were estimated
by MTT assay as described in Methods and
presented as the ratio against untreated cells.
Experiments were performed in triplicate, and
mean 6 SD values are presented. *VT-1 showed
significantly greater cytotoxicity than VT-2 after
three days treatment at each concentration, as
verified by statistical analysis (P , 0.01).
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was repeated more than three times independently and similar
results were obtained.
Detection of apoptotic cells in a renal tissue from hemolytic
uremic syndrome patient
In vitro observations described above suggest that apoptosis in
renal tubular epithelium involved in the pathogenesis of HUS.
Since we had the opportunity to examine the frozen renal tissue of
a child who died of HUS, we tested the occurrence of apoptosis in
tubular epithelium. As shown in Figure 8, cleavage of the nuclear
DNA in tubular epithelial cells as well as stromal cells was
confirmed by the TUNEL method, clearly indicating the occur-
rence of apoptosis in renal tissue of a HUS patient.
DISCUSSION
Cytotoxic effects of VT are thought to be mediated by the
A-subunit which inhibits protein synthesis [28–30]. Recently,
however, several reports have claimed that VTs induce pro-
grammed cell death, apoptosis, in several cell lines including
Vero, MDCK [31–33] and Burkitt’s lymphoma [17]. We demon-
strated herein further evidence that VTs induce apoptosis in
ACHN human renal adenocarcinoma cells which exhibit the
phenotype of distal tubular epithelia. Microscopic nuclear frag-
mentation, DNA ladder formation, expression of 7A6 antigen,
and incorporation of nucleotides by the TUNEL method, all of
which occurred following VT-treatment of ACHN cells, constitute
features with apoptosis. It is therefore clear that VT induces
apoptosis in a variety of cell types, although the mechanism
underlying this phenomenon is controversial and remains to be
elucidated.
In the case of Vero cells, a complete form of VT is required to
induce apoptosis [33], suggesting that inhibition of protein syn-
thesis mediated by the A-subunit is linked to apoptosis. In fact, it
was reported that inhibition of protein synthesis caused apoptosis
or operated as an apoptosis co-factor in some instances [34–36].
The enhancement of VT-mediated apoptosis of ACHN cells by
cycloheximide, an inhibitor of protein synthesis, as described
herein, supports this idea and raises the possibility of an unknown
pathway by which cells undergo programmed cell death. In
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Fig. 3. Detection of apoptosis in ACHN cells after treatment with vero-
toxin (VT)-1. (A) Morphological appearance of Giemsa stained ACHN
cells cultured in the presence of VT-1. Cells were cultured on Lab-Tek
Tissue Culture Chamber/Slide (Division Miles Laboratories, Inc., Naper-
ville, IL, USA) in medium alone (a, adherent cells) or in the presence of
200 pg/ml of VT-1 (b, for one day, adherent cells; c, for three days,
adherent cells; d, for three days, cytocentrifuged floating cells), then
stained and examined by light microscopy. Compared with untreated cells
(a), cells treated with VT-1 show characteristic condensed chromatin (b),
cleaved nuclei (c), and apoptotic bodies (d). Magnification 3600. (B)
DNA ladder formation after treatment with VT-1. ACHN cells at 50%
confluence were treated with (lanes 3 and 4) and without (indicated as 0
hr, lane 2) 200 pg/ml of VT-1. After 12 hours (lane 3) and 48 hours (lane
4) culture, DNAs were extracted as described in the Methods, and 1.5 mg
of the DNA from each sample was electrophoresed in 1% agarose gel. A
mixture of HindIII-digested l DNA and HaeIII-digested f DNA was
loaded on the same gel (lane 1), as a molecular weight control. (C) The in
situ detection of nuclear DNA cleavage in ACHN cells after treatment
with VT-1. To test the cleavage of nuclear DNA, ACHN cells treated with
(b) and without (a) 200 pg/ml of VT-1 for 24 hours were tested by the
TUNEL method. Typical positive cells are indicated by the arrow.
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contrast, the B-subunit of VT is sufficient to induce apoptosis
in Burkitt’s lymphoma lines [17], suggesting the presence of
an alternate mechanism for VT-mediated apoptosis, which is
independent of protein synthesis inhibition in these lines. A recent
report describing intracellular signaling events triggered by cross-
linking of CD77 may support this idea [37].
Interestingly, we observed a significant difference between
VT-1 and VT-2 in terms of efficiency for inducing apoptosis in
ACHN cells. In our experiment, both VTs induced apoptosis in
Burkitt’s line Ramos with equal efficacy (data not shown), exclud-
ing the possibility of loss of activity due to purification procedures.
As the amounts of VT-1 and VT-2 capable of binding to ACHN
cells are nearly equal, as showed by flow cytometry (Fig. 1B), the
different cytotoxicities of VTs may result from either the differ-
ence in thresholds of the stimuli or differences in signaling
pathways after binding of VTs to the cell surface. In this regard,
Fig. 4. Comparison of the efficiency of inducing apoptosis between verotoxin (VT)-1 and VT-2. (A) Induction of apoptotic antigen 7A6. After three days
of culture in medium alone (left panels) or in the presence of 200 pg/ml of VT-1 (center panels) or 200 pg/ml of VT-2 (right panels), ACHN cells were
fixed and stained with either APO2.7 monoclonal antibody (lower panels) or isotype matched control immunoglobulin (upper panels), then analyzed
by flow cytometry as described in the Methods section. To identify positive cells more clearly, the fluorescence intensity was displayed as a two
dimensional histogram against side light scatter. The ratios of positive cells, enclosed in the parallelogram, are indicated. Experiments with VT-treated
cells were performed in triplicate, and the means 6 SD are presented. X-axis, fluorescence intensity; Y-axis, side light scatter. *VT-1 induced significantly
greater apoptosis than VT-2, as verified by statistical analysis (P , 0.001). (B) Detection of subploid cells. ACHN cells, prepared under experimental
conditions identical to those of panel A, were fixed and stained with PI, then analyzed by flow cytometry. The ratios of subploid cells, that is, those
undergoing apoptosis, are indicated. Experiments with VT-treated cells were performed in triplicate, and the means 6 SD are presented. VT-1 induced
significantly greater apoptosis than VT-2, as verified by statistical analysis (*P , 0.001).
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it is important to examine whether inhibition of protein synthesis
by the A-subunit is solely responsible for apoptosis or the
B-subunit is also involved in apoptosis, as in the case of ACHN
cells.
In Vero cells, susceptibility to VT was reported to be cell cycle
dependent [38]. Similarly, if not identically, the sensitivity of
ACHN cells to VT changed according to cell density. Cells at high
density were more resistant to VT whereas cells at low density
were more susceptible to VT, indicating the operation of a similar
regulatory mechanism.
It is generally accepted, based on histopathologic findings [39],
that capillary microangiopathy and endothelial damage in the
kidney are the major causes of HUS [3, 4]. The findings that
endothelial cells express Gb3/CD77 and are susceptible to VTs
support this hypothesis [3, 25–27]. However, laboratory data, such
as marked elevation of urinary N-acetyl glucosaminidase and
b2-microglobulin, both of which are specific markers of tubular
function, have provided evidence of impaired renal tubular func-
tion in the acute stage of HUS [10]. The histopathologic change in
a mouse model of VTEC infection was found to be damage to the
renal tubular epithelium, while glomeruli remained unaffected
[5–7]. Several reports have described renal tubular epithelia as
expressing Gb3/CD77 and binding VTs [8, 9]. Based on these
findings, renal tubular epithelium is probably another target of
VTs in vivo, and it should be viewed as a major site of the renal
dysfunction that occurs in the early phase of HUS. The data
presented herein, that is, VT-induced cell death in the human
renal tubular epithelial line ACHN, raises the possibility of such a
mechanism. Since normal renal tubular epithelial cells in primary
culture also exhibited sensitivities to VTs (Kiyokawa et al, manu-
script submitted), the data obtained in ACHN cells are considered
to reflect the features of normal cells.
Recently, elevated plasma and urinary concentrations of
TNF-a, IL-6, and IL-8 have been demonstrated in HUS patients
[40–42]. Since TNF-a and IL-1 were reported to up-regulate the
expression of Gb3/CD77 on human endothelial cells in culture
and to increase their susceptibility to VTs [3, 25–27, 43], a strong
correlation between these cytokines and the pathogenesis of HUS
has been suggested. The finding that human and murine macro-
phages bind VTs and subsequently produce these cytokines [44,
45] strongly supports this idea. It is noteworthy that neither
TNF-a nor IL-1b alone is directly cytotoxic to endothelial cells,
but both become cytotoxic in the presence of co-factors that
inhibit protein and RNA synthesis [46], suggesting another syn-
ergistic mechanism between cytokines and VTs. The enhance-
ment of VT-mediated apoptosis of ACHN cells by TNF-a, as
described herein, further emphasizes the important role of cyto-
kines in the pathogenesis of HUS.
Considering all of the above evidence together, endothelial cell
damage does not appear to be the sole cause of HUS, and that to
the renal epithelium may also play an important role. Although a
direct effect of VTs may be the primary event in damage to these
cells, modulation by cytokines should be taken into consideration.
Additional basic studies are clearly necessary, but the possibility
of apoptosis as a VT-mediated mechanism of cell damage should
provide a new approach to understanding the pathogenesis of
HUS and to establishing therapeutic strategies. Our finding on the
clinical specimen that showed the presence of apoptosis in renal
tubules of HUS patient may support this idea.
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Fig. 5. Effect of initial cell concentration on verotoxin (VT)-mediated
apoptosis in ACHN cells. ACHN cells were plated at different cell
concentrations (column 1, 20%; column 2, 50%; column 3, 80%) then
treated with 200 pg/ml of VT-1 for three days. The subsequent ratios of
cells undergoing apoptosis were evaluated by detection of subploid cells as
described in Figure 4B. Experiments were performed in triplicate, and the
means 6 SD are presented. Significant differences in the appearance of
subploid cells among concentrations were demonstrated by statistical
analysis (P , 0.05).
Fig. 6. Effect of low dose of cycloheximide on verotoxin (VT)-mediated
apoptosis in ACHN cells. ACHN cells preincubated with (columns 2 and
4) and without (columns 1 and 3) 10 mg/ml of cycloheximide for 12 hours
were treated with (columns 3 and 4) and without (columns 1 and 2) 200
pg/ml of VT-1 for an additional 36 hours. The subsequent ratios of cells
undergoing apoptosis after treatment were evaluated by detection of
subploid cells as described in Figure 4B. Experiments were performed in
triplicate, and the mean 6 SD are presented. Pretreatment with a low dose
of cycloheximide significantly increased the appearance of VT-1 induced
subploid cells, as verified by statistical analysis (P , 0.05), without
affecting cells not treated with VT-1.
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